4YB Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Low LeverageAn essentially debt-free balance sheet reduces refinancing and interest-rate exposure, preserving flexibility while the company funds development. Substantial equity and assets provide a financial cushion that can support continued investment in the pipeline and reduce dependence on near-term borrowing.
Improved LiquidityThe large settlement materially strengthens liquidity and extends the company’s ability to finance clinical development without relying immediately on debt or equity issuance. Greater funding visibility supports sustained investment across several programs and improves resilience through regulatory and trial milestones.
Broad Clinical PipelineA broad catalyst calendar creates multiple opportunities for clinical validation, regulatory progress, and eventual commercial expansion rather than depending on one isolated program. Progress across several studies can diversify development outcomes and build a more durable product portfolio over time.
Bears Say
No Commercial RevenueThe absence of revenue leaves the company dependent on capital resources, settlements, and successful future approvals to fund operations. Widening losses also reduce earnings visibility and mean the business has not yet demonstrated that its pipeline can convert into sustainable commercial cash generation.
Heavy Cash BurnDeeply negative cash flow converts ongoing development spending directly into substantial cash outflows, making cost discipline and future financing capacity important. Even with stronger liquidity, continued burn can shorten the runway if commercial revenues or additional proceeds arrive later than expected.
Clinical Execution RiskVariability in placebo response, disease biology, and trial geography can weaken statistical power or make earlier efficacy signals harder to reproduce. These risks may delay readouts, require additional studies, or reduce the probability that important programs progress toward approval and revenue.
Immunovant News
4YB FAQ
What was Immunovant’s price range in the past 12 months?
Currently, no data Available
What is Immunovant’s market cap?
Immunovant’s market cap is €5.24B.
When is Immunovant’s upcoming earnings report date?
Immunovant’s upcoming earnings report date is Nov 09, 2026 which is in 16 days.
How were Immunovant’s earnings last quarter?
Immunovant released its earnings results on Aug 06, 2026. The company reported -€0.67 earnings per share for the quarter, missing the consensus estimate of -€0.561 by -€0.108.
Is Immunovant overvalued?
According to Wall Street analysts Immunovant’s price is currently Undervalued.
Does Immunovant pay dividends?
Immunovant does not currently pay dividends.
What is Immunovant’s EPS estimate?
Immunovant’s EPS estimate is -0.66.
How many shares outstanding does Immunovant have?
Currently, no data Available
What happened to Immunovant’s price movement after its last earnings report?
Immunovant reported an EPS of -€0.67 in its last earnings report, missing expectations of -€0.561. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Immunovant?
Currently, no hedge funds are holding shares in DE:4YB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunovant Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€43.53 (― Upside)
€43.53 (― Upside)
Blogger Sentiment
Bullish
DE:4YB Sentiment 63%
Sector Average 66%
Sector Average 66%
Insider Transactions
Sold Shares
Worth €613.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
51.60%
12-Months-Change
Fundamentals
Return on Equity
-69.59%
Trailing 12-Months
Asset Growth
28.88%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Immunovant
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
4YB Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial near-term and medium-term upside: a large multipart settlement that materially increases liquidity, an active and well-funded pipeline with multiple imminent readouts and a potential approval/launch for brexpiprazole in dermatomyositis, successful enrollments in registrational studies, and ongoing shareholder capital returns. These positives were balanced against recognized clinical and operational risks—placebo variability, translation risk for PH-ILD, JAK-class safety perceptions, geographic variability in trials, and continued high R&D and G&A spend. On balance, management presents confident execution and a strong catalyst calendar that outweigh the disclosed risks.View all DE:4YB earnings summaries4YB Stock 12 Month Forecast
Average Price Target
―TG Therapeutics
―
Viridian Therapeutics
―
Aurinia Pharmaceuticals
―
Protagonist Therapeutics
―
Kymera Therapeutics
―